Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 27, Issue 3-4, Pages 265-271Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2014.10.008
Keywords
acute myeloid leukemia, AML; complete response, CR; LAIP, leukemia associated immunopheno-type; minimal residual disease; morphology; MRD; flow; PCR, polymerase chain reaction; real-time quantitative PCR, RQ-PCR; risk classification; transplant
Categories
Ask authors/readers for more resources
The possibility of defining residual disease far below the morphological level of 5% blast cells is changing the landscape of risk classification in acute myeloid leukemia (AML). The so-called minimal residual disease (MRD) approach at this time can establish the presence of leukemia cells down to levels of 1:1000-1:10(6) white blood cells, compared to 1:20 for morphology. Availability of the newer and more sensitive technology to quantify the level of leukemic burden raises the issue of whether MRD should emerge as a new definition of complete response. This paper explores some of the issues surrounding such a change in definition. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available